Guggenheim analyst Subbu Nambi has maintained a Buy rating on Adaptive Biotechnologies, citing a positive outlook for the stock. The firm has increased its price target for the company to $22, up from the previous target of $21.

Rating and Price Target Details

The decision to raise the price target reflects confidence in the company's performance and future prospects. The revised target suggests potential upside from current trading levels.

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol ADPT.

Adaptive Biotechnologies Corporation announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to unlock value and support distinct growth strategies. The company expects to determine its preferred path to separation by year-end 2026. This move aims to address the specific capital needs and value creation opportunities of each segment outside of the current corporate structure. William Blair maintained its Outperform rating on the stock, stating the separation could simplify the investment story and create greater strategic flexibility for the MRD franchise.

Since establishing MRD and Immune Medicine as separate operating segments in 2024, both units have advanced their respective operational goals. MRD has achieved significant scale, expanded reimbursement, and strengthened its clinical evidence base. The segment has reached profitability, establishing its clonoSEQ® platform as a leading solution in MRD testing. Immune Medicine has focused on building a differentiated discovery platform anchored by the world's largest clinically linked immune receptor dataset.

Analyst Andrew Brackmann noted that investors will likely seek more clarity on the future of the Immune Medicine segment. William Blair indicated the separation of Immune Medicine appears at least neutral to Adaptive's valuation, noting the segment likely contributed little or even negative value within investor valuation models. In a downside scenario where a spin-off proves impractical, the company would still benefit by eliminating the segment's expected cash burn of $15 million to $20 million this year and separating those results from its core financial performance.

Business Segment Overview

The following table outlines the current status of the two operating segments:

Financial and Operational Metrics

The MRD business revenue has grown from $103 million in 2023 to $212 million in 2025, and the business reported $15 million in 2025 adjusted EBITDA. With more than 300 million covered lives, over 175 EMR-integrated accounts, and greater than 180 active biopharma trials, clonoSEQ is increasingly embedded in routine clinical practice and drug development. William Blair believes the MRD business may receive greater attention as it continues to post volume growth exceeding 35% and expand margins.

Immune Medicine has made strides in drug discovery and data capabilities. With over 6 million functional T-cell receptor (TCR)-antigen pairs and well-characterized data sets on more than 10,000 patients, Immune Medicine is discovering pathogenic TCRs and the disease-causing antigens they bind. Concurrently, the company priced its $300 million 0% convertible senior notes due 2031 to repay the OrbiMed agreement and simplify its capital structure. The company stated it would use the remaining proceeds for opportunistic initiatives in the MRD business.